Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRHI Magnesita Regulatory News (RHIM)

Share Price Information for RHI Magnesita (RHIM)

Share Price is delayed by 15 minutes
Get Live Data
2,730.00    0.00 (0.00%)
Bid:
2,770.00
Ask:
2,805.00
Spread: 35.00 (1.264%)
Market Cap: £1.29b
RHIM Live PriceLast checked at - London Stock Exchange

Intraday RHI Magnesita Share Chart

Trading Statement

22 Oct 2020 07:00

RNS Number : 8500C
RHI Magnesita N.V.
22 October 2020
 

RHI Magnesita N.V.

 

("RHI Magnesita" or the "Company" or "Group")

 

 

Q3 2020 TRADING UPDATE

 

Continued resilience and improving customer outlook; Production Optimisation Plan extended; FY guidance and interim dividend re-instated

 

RHI Magnesita (LSE: RHIM), the leading global supplier of refractory products, systems and solutions, today provides an update on trading for the three months to 30 September 2020 ('Q3') and the strategic cost measures being taken to ensure the long-term success of the Group.

 

Q3 Trading

Consistent with expectations at the half year results on 5 August 2020, Q3 trading was similar to Q2 reflecting continued stability in our markets during what is seasonally a quieter period in July and August. Encouragingly, the order book improved steadily but still slowly through the period. With the exception of the Industrial Projects business, we now have stronger visibility to the beginning of 2021.

 

Within the Steel Division, North America and South America started to see signs of recovery in Q3. Europe and India continued to reflect the slower rate of recovery in the steel industry in both regions. Activity levels improved further in China, although from a low base.

 

The Industrial Division remained subdued. While Q3 is a seasonally quieter period for the Cement/Lime segment, it was further impacted by customers delaying orders. We continue to expect to see modest seasonal improvements in Q4. The projects business experienced further postponements, as customers delay capital projects, and will not see the peak levels experienced in 2019.

 

Raw material prices fell slightly in July and August and improved in September. The Group continues to derive a solid margin from its backward integration, with a 2.3% Adjusted EBITA margin contribution in Q3 2020, unchanged from the H1 2020 results.

 

As previously announced, the Group expects to realise €50 million of short-term fixed cost savings for the full year 2020 as part of its Covid-19 response. €10 million of these will be maintained into 2021 in the form of lower depreciation.

 

Strategic initiatives

The Group continues to make good progress on its longer-term, strategic cost savings initiatives. These comprise the Production Optimisation Plan and SG&A Reduction Plan.

Plans to extend the Production Optimisation Plan have now been finalised and the Group intends to close additional production facilities with a focus on Europe and South America. The intention is to take the total plant rationalisation up to 10 sites by H1 2022 and increases the cumulative strategic cost savings (including the SG&A Reduction Plan) to €100 million by 2022.

The total capital expenditure for the strategic cost savings initiatives increases to €160 million by 2022, with exceptional restructuring costs of €100 million and impairments of €110 million. The details of the strategic cost savings initiatives are included as an appendix.

 

Strong financial position

RHI Magnesita has a resilient balance sheet, liquidity of €1.1 billion, no material debt maturity before 2023 and significant headroom under its net debt to EBITDA covenant. The Group continues its focus on working capital management, especially inventories and accounts receivable. Working capital has reduced further in the third quarter and the Group expects further cash inflows in Q4.

 

Dividend reinstated

Due to the resilient underlying cash generation, strength of the balance sheet and improving confidence in the market outlook, the Board is today declaring an interim dividend of €0.50 per share, which is in line with the 2019 interim dividend. The dividend will be payable to shareholders on 21 December 2020 on the register at the close of trading on 4 December 2020. The ex-dividend date is 3 December 2020.

While the Group continues to target leverage of between 0.5x and 1.5x net debt to EBITDA, the impact of COVID-19 on 2020 EBITDA means that leverage is likely to be modestly above this range at the end of 2020 and through 2021 as the Group continues to prioritise investment in projects to improve its competitive position and shareholder returns. The Board is confident that leverage should reduce thereafter.

 

Outlook

While there remains uncertainty on the continuing impact of the COVID-19 pandemic, we are confident that the Group will continue to demonstrate its resilience, while remaining well-positioned for when the recovery takes place. Our confidence is underpinned by the Group's clear strategy and the benefit of ongoing business improvement initiatives. This supports the decision to pay an interim dividend and our expectations for FY 2020 adjusted EBITA1 to be in line with current market expectation2.

 

Conference call

The Company will host a conference call at 8.15am UK time this morning to discuss the trading update. The conference call details are: +44 20 3936 3000 with the access code: 080443

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (596/2014/EU).

 

Further information:

Investors: Annabel Hill, Interim Head of Investor Relations +44 7792034254

annabel.hill@rhimagnesita.com

Press: Matt Denham, Teneo +44 7825 735596

 

 

About RHI Magnesita

RHI Magnesita is the leading global supplier of high-grade refractory products, systems and solutions which are critical for high-temperature processes exceeding 1,200°C in a wide range of industries, including steel, cement, non-ferrous metals and glass. With a vertically integrated value chain, from raw materials to refractory products and full performance-based solutions, RHI Magnesita serves customers around the world, with around 13,000 employees in 35 main production sites and more than 70 sales offices. RHI Magnesita intends to leverage its leadership in terms of revenue, scale, product portfolio and diversified geographic presence to target strategically those countries and regions benefitting from more dynamic economic growth prospects.

Its shares have a premium listing on the London Stock Exchange (symbol: RHIM) and are a constituent of the FTSE 250 index. For more information please visit: www.rhimagnesita.com.

 

Appendix

Summary of Strategic Cost Savings Initiatives

Presented in €m

2019

2020

2021

2022

 

Cumulative run rate EBITA improvement from cost savings3

 

30

75

100

 

- Production Optimisation Plan (POP) (announced at Capital Markets Day in Nov 2019)

 

5

25

40

 

- Extension of POP (announced today)

 

-

5

15

 

- SG&A (announced in July 2020)

 

10

30

30

 

- Operational turnaround

 

15

15

15

 

Implementation costs - annual amounts €m

 

 

 

 

Cumulative amount

- Capital Expenditure

-

45

95

20

160

- Restructuring costs (exceptional)4

5

35

60

-

100

- Impairments

50

60

-

-

110

 

The extension of the Production Optimisation Plan requires capital expenditure of €25 million, taking total capital expenditure for the strategic cost savings initiatives to €160 million by 2022. Exceptional restructuring costs will increase by €15 million, amounting to €100 million by 2021. Impairments will increase by €40 million, taking total impairments to €110 million.

 

1. Adjusted EBITA excludes other income and expenses

2. Current market expectation based on Company compiled consensus of €248 million

3. The total cost savings run rate excludes the 2020 short term fixed-cost reduction of €50 million, taken as mitigating measures against the impact of COVID-19. €10 million of these will be maintained into 2021 in the form of lower depreciation.

4. Exceptional restructuring costs relate to the cash flow impact

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFFLLLBBLBFBK
Date   Source Headline
1st Jun 20268:49 amRNSTotal Voting Rights
13th May 20264:07 pmRNSResult of AGM
1st May 20268:57 amRNSTotal Voting Rights
29th Apr 20267:00 amRNSQ1 Trading Update
1st Apr 20269:11 amRNSTotal Voting Rights
26th Mar 20262:54 pmRNSNotice of AGM
10th Mar 202611:18 amRNSDirector/PDMR Shareholding
2nd Mar 20267:55 amRNSAnnual Financial Report
2nd Mar 20267:49 amRNSTotal Voting Rights
2nd Mar 20267:00 amRNS2025 Full Year Results
13th Feb 20268:56 amRNSNotice of Results
2nd Jan 20267:00 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSTotal Voting Rights
10th Dec 20259:10 amRNSDirectorate change
10th Nov 20257:00 amRNSTrading Update
7th Nov 202511:48 amRNSDirectorate change
3rd Nov 202511:54 amRNSDirectorate change
1st Oct 20257:00 amRNSTotal Voting Rights
1st Aug 20257:00 amRNSTotal Voting Rights
30th Jul 20257:00 amRNS2025 Half Year Results
16th Jul 20257:00 amRNSNotice of Results
30th Jun 20258:29 amRNSDirector Declaration
2nd Jun 20258:53 amRNSTotal Voting Rights
29th May 20259:26 amRNSDirector/PDMR Shareholding
23rd May 20258:12 amRNSDirector Declaration
7th May 20254:11 pmRNSResult of AGM
7th May 20257:00 amRNSQ1 2025 Trading Update
1st May 20259:07 amRNSTotal Voting Rights
7th Apr 20253:36 pmRNSDirector/PDMR Shareholding
3rd Apr 20254:17 pmRNSDirector/PDMR Shareholding
1st Apr 20254:49 pmRNSDirector/PDMR Shareholding
1st Apr 20259:13 amRNSTotal Voting Rights
28th Mar 20254:12 pmRNSDirector/PDMR Shareholding
27th Mar 20253:30 pmRNSNotice of AGM
27th Mar 20252:50 pmRNSDirectorate Change
24th Mar 202512:32 pmRNSNotice of AGM
7th Mar 202510:13 amRNS2025 Long Term Incentive Plan Awards
27th Feb 20257:00 amRNS2024 Full Year Results
17th Feb 20257:00 amRNSNotice of Results
3rd Feb 20259:11 amRNSTotal Voting Rights
28th Jan 20251:59 pmRNSCompletion of Resco transaction
2nd Jan 20257:00 amRNSTotal Voting Rights
28th Nov 202410:09 amRNSDirector/PDMR Shareholding
21st Nov 20249:03 amRNSDirector/PDMR Shareholding
11th Nov 20247:00 amRNSQ3 2024 Trading Update
7th Oct 202410:10 amRNSDirector/PDMR Shareholding
1st Oct 20247:00 amRNSTotal Voting Rights
27th Sep 202411:15 amRNSExercise of LTIP options by PDMR
19th Aug 202410:31 amRNSDirector/PDMR Shareholding
12th Aug 20242:27 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.